A1M Pharma applies for trademark protection for ROSGard™ as the name of the company's candidate drug RMC-035
A1M Pharma has filed an application for trademark protection in Europe of the brand name ROSGard™ for the company's candidate drug RMC-035. Applications in other important markets will follow.
The candidate drug in question is based on the endogenous protein A1M. The name refers to the potential to protect against harmful oxidative stress in the organs and other tissues.
"ROSGard™ is an appropriate brand name that clearly associates our candidate drug with its mechanism of action. This enables us to be more precise in our communication with potential partners, investors and media and at an early stage increase the awareness of the candidate´s proposed brand name during a future market launch", says A1M Pharma's CEO Tomas Eriksson.
Harmful substances that cause oxidative stress in connection with several severe medical conditions – including preeclampsia and acute kidney injuries – are collectively known as reactive oxygen species, abbreviated ROS.
The initial registration for trademark protection is made in Europe. Thereafter, the registration can be used for applications in other markets.
For more information, please contact
Tomas Eriksson, CEO of A1M Pharma AB
Telephone: +46 46-286 50 30
About A1M Pharma
A1M Pharma develops a diagnostic method and treatment for pre-eclampsia, a condition that affects around 10 million pregnant women worldwide each year. This disorder is responsible for 76,000 maternal and 500,000 infant deaths each year and it is the cause of 15 % of all premature births. Currently, there is no effective diagnostic method or curative treatment for impaired kidney function associated with pre-eclampsia. The only option is therefore to terminate pregnancy by inducing delivery which leads to premature infants and substantial health care costs. Several studies indicate that A1M Pharma’s candidate drug, ROSGard™, based on the protein A1M (alpha-1-microglobulin), restores the impaired kidney function by repairing damaged tissue and protect against oxidative stress. New findings indicate that the cells within the heart are protected in a similar way. Apart from the connection with pre-eclampsia, kidney injury is a condition often accompanying major surgery and transplantation and the company is therefore also developing a treatment for the closely related indication acute kidney injury. Acute kidney injury that can lead to permanent kidney damage affects 12 million people every year.